StreetInsider.com News Articles

Form 4 Mobia Medical, Inc. For: Feb 23 Filed by: Curnes Nelson Bunker

Thu, 11 Jun 2026 19:10:00 -0400

si-local-file:///var/storage/secattach/20260611/26637156.html

Form 10-Q Mobia Medical, Inc. For: Mar 31

Thu, 04 Jun 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260604/26606322.html

BofA Securities Starts Mobia Medical (MOBI) at Buy

Tue, 02 Jun 2026 06:04:36 -0400

BofA Securities analyst Travis Steed initiates coverage on Mobia Medical (NASDAQ: MOBI) with a Buy rating and a price target of $16.00.

For an analyst ratings summary and ratings history on Mobia Medical click here. For more ratings news on Mobia Medical click here.

Shares of Mobia Medical closed at $13.50 yesterday.

BTIG Starts Mobia Medical (MOBI) at Buy

Tue, 02 Jun 2026 05:36:01 -0400

BTIG analyst Ryan Zimmerman initiates coverage on Mobia Medical (NASDAQ: MOBI) with a Buy rating and a price target of $19.00.

The analyst comments "Mobia Medical (MOBI) develops and commercializes Vivistim, the first and only FDA-approved VNS platform for chronic ischemic stroke survivors living with moderate-to-severe upper extremity impairment. Vivistim stimulates the vagus nerve during functional movement, triggering neuromodulator release which drives neuroplasticity and enables durable restoration of upper limb function. MOBI is not competing in an established market, it is the market. There are no other FDA-approved devices for chronic stroke recovery, and until Vivistim's PMA approval in August 2021,

BTIG Starts Mobia Medical (MOBI) at Buy

Tue, 02 Jun 2026 05:36:01 -0400

BTIG analyst Ryan Zimmerman initiates coverage on Mobia Medical (NASDAQ: MOBI) with a Buy rating and a price target of $19.00.

Wolfe Research Starts Mobia Medical (MOBI) at Outperform, 'Expect Story to Rehab Image Over Time'

Tue, 02 Jun 2026 05:35:25 -0400

(Updated - June 2, 2026 5:35 AM EDT)

Wolfe Research analyst Mike Polark initiates coverage on Mobia Medical (NASDAQ: MOBI) with a Outperform rating and a price target of $19.00.

The analyst comments "Mobia Medical sells the Vivistim System, an implanted vagus nerve stimulator FDA approved mid-2021. Stimulation of the vagus nerve improves brain neuroplasticity and helps enhance outcomes of task-specific rehabilitation in ischemic stroke survivors with moderate-to-severe upper extremity deficit. The first full year of US commercial launch was 2023. This market – vagus nerve stimulation for task-specific stroke rehabilitation – does not exist at scale yet – Mobia is building

Wolfe Research Starts Mobia Medical (MOBI) at Outperform, 'Expect Story to Rehab Image Over Time'

Tue, 02 Jun 2026 05:35:25 -0400

(Updated - June 2, 2026 5:35 AM EDT)

Wolfe Research analyst Mike Polark initiates coverage on Mobia Medical (NASDAQ: MOBI) with a Outperform rating and a price target of $19.00.

Goldman Sachs Starts Mobia Medical (MOBI) at Buy

Tue, 02 Jun 2026 01:06:44 -0400

Goldman Sachs analyst David Roman initiates coverage on Mobia Medical (NASDAQ: MOBI) with a Buy rating and a price target of $31.00.

The analyst comments: “Based on the company's innovative neuro-stimulation technology, large market opportunity, performance of prior market creation SMID cap MedTech comps, and GSe projected revenue trajectory, we view the stock emerging as a differentiated growth asset.

Mobia Medical is a commercial-stage MedTech company that offers an implantable vagus nerve stimulation (VNS) system and paired rehabilitation therapy for chronic stroke recovery. The company's core platform (Vivistim) utilizes an implanted pulse generator and lead to deliver targeted electrical stimulation to the

Goldman Sachs Starts Mobia Medical (MOBI) at Buy

Tue, 02 Jun 2026 01:06:44 -0400

Goldman Sachs analyst David Roman initiates coverage on Mobia Medical (NASDAQ: MOBI) with a Buy rating and a price target of $31.00.

JPMorgan Starts Mobia Medical (MOBI) at Overweight

Tue, 02 Jun 2026 01:02:39 -0400

JPMorgan analyst Robbie Marcus initiates coverage on Mobia Medical (NASDAQ: MOBI) with a Overweight rating and a price target of $15.00.

The analyst comments: “Mobia is commercializing Vivistim Paired Vagus Nerve Stimulation (Paired VNS), the first-and-only clinically validated, FDA-approved therapy for chronic ischemic stroke survivors with moderate-to-severe upper extremity impairment, a population that often reaches a functional recovery plateau after the first 3–6 months post-stroke. Chronic stroke recovery remains a large, under-served market (~800,000 strokes annually in the US and ~10M stroke survivors; ~87% ischemic) with few good treatment options. Vivistim is supported by randomized pivotal data, early adoption (1,000+ cumulative

JPMorgan Starts Mobia Medical (MOBI) at Overweight

Tue, 02 Jun 2026 01:02:39 -0400

JPMorgan analyst Robbie Marcus initiates coverage on Mobia Medical (NASDAQ: MOBI) with a Overweight rating and a price target of $15.00.

Form SCHEDULE 13G Mobia Medical, Inc. Filed by: Synapse Investment, LP

Mon, 18 May 2026 20:37:00 -0400

si-local-file:///var/storage/secattach/20260518/26515714.html

Form SCHEDULE 13D Mobia Medical, Inc. Filed by: Osage University Partners III, LP

Fri, 15 May 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260515/26506099.html

Form SCHEDULE 13G Mobia Medical, Inc. Filed by: Gilde Healthcare Holding B.V.

Fri, 15 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260515/26505020.html

Form 4 Mobia Medical, Inc. For: May 11 Filed by: Presidio Management Group XII, L.L.C.

Wed, 13 May 2026 19:59:00 -0400

si-local-file:///var/storage/secattach/20260513/26488015.html

Form SCHEDULE 13D Mobia Medical, Inc. Filed by: Longitude Capital Partners V, LLC

Wed, 13 May 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260513/26487503.html

Form 4 Mobia Medical, Inc. For: Jan 30 Filed by: Osage University GP IV, LLC

Tue, 12 May 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260512/26478225.html

Form 4 Mobia Medical, Inc. For: Feb 06 Filed by: Tansey Casey M

Mon, 11 May 2026 21:58:00 -0400

si-local-file:///var/storage/secattach/20260511/26471309.html

Form 4 Mobia Medical, Inc. For: May 07 Filed by: Leavitt Chase C.